Advantest Corp (ATE)

11.45
0.02 0.17
OTC : Technology
Prev Close 11.43
Open 11.45
Day Low/High 11.45 / 11.45
52 Wk Low/High 7.01 / 11.55
Volume 1.00K
Avg Volume 20.40K
Exchange OTC
Shares Outstanding 174.57M
Market Cap 1.71B
EPS 0.62
P/E Ratio N/A
Div & Yield 0.16 (1.70%)

Latest News

Advantest Earns 28th Consecutive Ranking As A 10 BEST Supplier Of Semiconductor Test Equipment, Excelling As Global Customers Rate System Uptime As Paramount In The Industry

Advantest Earns 28th Consecutive Ranking As A 10 BEST Supplier Of Semiconductor Test Equipment, Excelling As Global Customers Rate System Uptime As Paramount In The Industry

For the 28 th consecutive year, leading semiconductor test equipment supplier, Advantest Corporation (TSE:6857), has been named a distinguished 10 BEST Supplier of Chip Making Equipment in the annual VLSIresearch Customer...

Antibe Therapeutics To Present At 2016 Bloom Burton & Co. Healthcare Investor Conference

Antibe Therapeutics To Present At 2016 Bloom Burton & Co. Healthcare Investor Conference

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF), a commercial-stage pharmaceutical growth company, is pleased to announce that CEO Daniel Legault will be presenting at the fifth annual Bloom Burton & Co.

Antibe Therapeutics Announces The Launch Of PentOS OI™ Putty, A High-Quality Bone Graft Substitute For Oral And Maxillofacial Surgery

Antibe Therapeutics Announces The Launch Of PentOS OI™ Putty, A High-Quality Bone Graft Substitute For Oral And Maxillofacial Surgery

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) today announced that its subsidiary Citagenix Inc.

Antibe Therapeutics Announces Appointment Of The Giordano Group, Inc, A Division Of Network 1 Financial Securities LLC, As US-BASED Investor Relations Consultant

Antibe Therapeutics Announces Appointment Of The Giordano Group, Inc, A Division Of Network 1 Financial Securities LLC, As US-BASED Investor Relations Consultant

Antibe Therapeutics Inc ("Antibe" or the "Company") (TSXV:ATE, OTCQX:ATBPF) has retained the Giordano Group, Inc ("Giordano Group"), a division of Network 1 Financial Securities LLC ("Network 1"), to provide investor...

Antibe Therapeutics Announces Grant Of Stock Options

Antibe Therapeutics Announces Grant Of Stock Options

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) announces that it has granted its directors, officers and employees options to purchase a total of 6,751,000 common shares of Antibe pursuant to the...

Antibe Therapeutics' ATB-346 Receives Approval For Phase 2 Clinical Trial In Osteoarthritis Patients

Antibe Therapeutics' ATB-346 Receives Approval For Phase 2 Clinical Trial In Osteoarthritis Patients

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) has received approval from Health Canada to conduct a Phase 2 trial of its lead drug, ATB-346, in patients with osteoarthritis of the knee.

Antibe Therapeutics Receives Approval To Proceed To Phase 2 Clinical Trial

Antibe Therapeutics Receives Approval To Proceed To Phase 2 Clinical Trial

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) is pleased to announce that it has received approval from Health Canada to initiate a Phase 2 trial.

Antibe Therapeutics Reports Q3 2016 Interim Financial And Operating Results

Antibe Therapeutics Reports Q3 2016 Interim Financial And Operating Results

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) filed its financial and operating results Monday, February 29 for the fiscal quarter ended December 31, 2015.

Profound Preventative And Restorative Effects Of ATB-346 In Mice With Genetic Predisposition To Intestinal Cancer

Profound Preventative And Restorative Effects Of ATB-346 In Mice With Genetic Predisposition To Intestinal Cancer

In an article published today in the journal PLOS ONE, an international team of scientists led by Antibe Therapeutics Inc.

W2BI, Inc. To Demonstrate New Automated Mobile Device Test System For IoT Applications, Along With Smart Device Production Test Systems At Mobile World Congress In Barcelona, February 22-25, 2016

W2BI, Inc. To Demonstrate New Automated Mobile Device Test System For IoT Applications, Along With Smart Device Production Test Systems At Mobile World Congress In Barcelona, February 22-25, 2016

W2BI, Inc., a member of the Advantest Group (NYSE:ATE), and a leading software provider of wireless device test automation products for the world's top mobile operators and suppliers, announced that it will participate in...

W2BI Demonstrates New Automated Mobile Device Test System For Internet-of-Things Devices, And Its Newest Smart Device Production Test Systems At Mobile World Congress In Barcelona, February 22-25, 2016

W2BI Demonstrates New Automated Mobile Device Test System For Internet-of-Things Devices, And Its Newest Smart Device Production Test Systems At Mobile World Congress In Barcelona, February 22-25, 2016

W2BI, Inc., a member of the Advantest Group (NYSE:ATE), and a leading software provider of wireless device test automation products for the world's top mobile operators and suppliers, announced that it will again exhibit at...

Antibe Therapeutics Closes Acquisition Of Minority Interest In Citagenix Inc.

Antibe Therapeutics Closes Acquisition Of Minority Interest In Citagenix Inc.

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQX:ATBPF) announces that it has completed the acquisition of the remainder 15% minority interest in Citagenix Inc.

Antibe Therapeutics Announces Payment In Kind Election

Antibe Therapeutics Announces Payment In Kind Election

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQX:ATBPF) announces it has elected to pay in kind all interest due January 15, 2016 under the Company's 10% senior secured convertible debentures due...

Antibe Therapeutics Signs Exclusive License & Distribution Agreement For Novel Bone Regenerating Biological Product

Antibe Therapeutics Signs Exclusive License & Distribution Agreement For Novel Bone Regenerating Biological Product

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF), a commercial-stage healthcare company focused on pain, inflammation and regenerative medicine, is pleased to announce the signing of an exclusive Licensing and...

Antibe Therapeutics Announces Brokered Private Placement

Antibe Therapeutics Announces Brokered Private Placement

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQX: ATBPF) is pleased to announce the completion of a first closing of a brokered private placement (the "Private Placement") on the same financial terms...

Antibe Therapeutics Announces Completion Of Validation Studies Of ATB-346, Progression To Phase 2 Clinical Trials

Antibe Therapeutics Announces Completion Of Validation Studies Of ATB-346, Progression To Phase 2 Clinical Trials

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) announced today the completion of the previously announced validation studies being performed on the Company's lead drug, ATB-346.

Antibe Therapeutics Reports Q2 2016 Interim Financial And Operating Results And Appoints New CFO

Antibe Therapeutics Reports Q2 2016 Interim Financial And Operating Results And Appoints New CFO

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) filed its financial and operating results Thursday, November 26 for the fiscal quarter ended September 30, 2015.

Antibe Enters Into A GUD Product Licensing Agreement With Knight Therapeutics

Antibe Enters Into A GUD Product Licensing Agreement With Knight Therapeutics

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQX:ATBPF), a commercial-stage healthcare company with a growing portfolio of innovative products targeting inflammatory and degenerative disorders,...

Advantest To Exhibit At IMAPS 2015, Orlando, FL, October 27-29

Advantest To Exhibit At IMAPS 2015, Orlando, FL, October 27-29

Leading semiconductor test equipment supplier Advantest Corporation (TSE:6857, NYSE:ATE) will promote its new TS9000 terahertz analysis systems for the semiconductor industry in Booth 619 at the International...

3D Semiconductor Wiring Failures And TDR Measurement Examples (Graphic: Business Wire)

3D Semiconductor Wiring Failures And TDR Measurement Examples (Graphic: Business Wire)

Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857, NYSE: ATE) announced today that it has initiated sales of its new TDR Option for the company's TS9000 series of terahertz analysis systems.

Antibe Therapeutics Closes Strategic Transactions

Antibe Therapeutics Closes Strategic Transactions

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQX: ATBPF) announces that it has completed the acquisition of an 85% interest in Citagenix Inc.

Antibe Therapeutics' Lead Drug Shows Promising Effects In Alveolar Bone Loss Study

Antibe Therapeutics' Lead Drug Shows Promising Effects In Alveolar Bone Loss Study

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQX: ATBPF) is pleased to announce promising results from an independent bone loss study.

IIROC Trading Resumption - ATE

IIROC Trading Resumption - ATE

Antibe Therapeutics Announces Strategic Transactions

Antibe Therapeutics Announces Strategic Transactions

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQX:ATBPF) is pleased to announce that it has entered into agreements to complete strategic transactions that mark the transition of the Company from a...

IIROC Trading Halt - ATE

IIROC Trading Halt - ATE

Advantest Develops

Advantest Develops "Hadatomo™" Photoacoustic Microscope For Non-Invasive Imaging Of Blood Vessels In The Dermis To A Depth Of 3mm New Instrument Further Enables Critical Research In Dermatology And Regenerative Science

Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857, NYSE:ATE) announced that it has developed a new photoacoustic microscope that enables non-invasive imaging of blood vessels in the dermis to a...

Antibe Therapeutics Reports Q1 2016 Interim Financial And Operating Results And A Further Update On Its Validation Studies

Antibe Therapeutics Reports Q1 2016 Interim Financial And Operating Results And A Further Update On Its Validation Studies

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results Friday, August 21 for the fiscal quarter ended June 30, 2015.

Antibe Announces Completion Of Phase I Studies Of ATB-346 And An Update On Its Validation Studies

Antibe Announces Completion Of Phase I Studies Of ATB-346 And An Update On Its Validation Studies

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) is pleased to announce that the report on their Phase I studies of ATB-346, its lead drug, has been finalized.